Gen Digital

Business

Blue Owl Capital Navigates Legal Storm: Liquidity Lawsuits Clash with Analyst Confidence

Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.

Jan 30, 2026

Business

Cardinal Energy Secures CA$95M in Upsized Equity Financing to Fuel Reford 2 Project and Trim Debt

Cardinal Energy Ltd. (TSX:CJ) has successfully upsized its bought deal financing to CA$95.15 million, capitalizing on robust investor appetite. The proceeds are earmarked to accelerate development of its key Reford 2 thermal oil project and strengthen its balance sheet, even as its valuation metrics present a complex picture for investors.

Jan 30, 2026

Business

Unity Integrates Coda for Direct Web Stores, Aiming to Reshape Developer Monetization

Unity Software's new in-app web store integration with Coda could empower developers to bypass traditional marketplace fees, potentially altering the company's revenue streams and addressing its persistent valuation gap amid volatile stock performance.

Jan 30, 2026

Business

Krones AG Shares Surge: Strong Financials Fuel Investor Confidence

Krones AG (ETR:KRN) has seen its stock price climb 11% in the past quarter. Analysis points to robust fundamentals, particularly a healthy Return on Equity (ROE) of 14%, as a key driver behind the market's bullish sentiment and the company's impressive earnings growth trajectory.

Jan 30, 2026

Business

United Rentals Caps Record 2025, Eyes Another Year of Growth Fueled by Mega-Projects

United Rentals reported strong Q4 results, driven by data center and power sector demand, and issued 2026 guidance forecasting continued revenue growth. Management highlighted a robust project pipeline while navigating margin pressures.

Jan 30, 2026

Business

Stryker Caps Strong 2025 with Record Robotics Growth, Eyes Further Expansion Amid Tariff Headwinds

The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.

Jan 30, 2026

Business

SL Green Executives Bullish on NYC Office Rebound, Detail $9.5B Capital Strategy

In its Q4 2025 earnings call, SL Green Realty projected strong fundamentals for Manhattan's office market, citing robust leasing and AI-driven demand. Management reiterated ambitious 2026 financing and asset sale targets while reporting quarterly results that beat expectations.

Jan 30, 2026

Business

Schneider National Navigates Tough Q4 as Freight Demand Falters, Eyes Supply-Driven Recovery

Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.

Jan 30, 2026

Business

Southside Bancshares Navigates Higher Rates, Posts Q4 Profit Rebound Amid Strategic Portfolio Shift

Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.

Jan 30, 2026

Business

Sherwin-Williams Navigates 'Softer for Longer' Market to Post Strong Q4, Eyes Modest 2026 Growth

Despite a persistently muted demand environment, Sherwin-Williams reported robust fourth-quarter earnings, driven by cost discipline and strategic acquisitions. The paint giant forecasts low-to-mid single-digit sales growth for 2026 while reinstating employee benefits, signaling cautious optimism amid ongoing economic headwinds.

Jan 30, 2026

Business

BofA Doubles Down on Hesai Group, Boosts Price Target on Lidar Leadership and Regulatory Tailwinds

Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Macquarie Trims XPeng Target, Citing Subsidy Cuts and 'Transition Year' Challenges

Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.

Jan 30, 2026

Business

Atour Emerges as a Premium Contender in China's Hotel Wars, Says CLSA

Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

RBC Lifts Price Target on Ascendis Pharma, Backs Growth Trajectory Through 2026

RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.

Jan 30, 2026

Business

On Holding: A 2026 Growth Story Backed by Analysts Despite Price Target Adjustments

Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.

Jan 30, 2026

Business

AUTO1 Group's Three-Year Surge: Shareholders Still Up 239% Despite Recent Dip

Despite a recent 6.8% pullback, AUTO1 Group SE (ETR:AG1) has delivered a staggering 239% return to its shareholders over the past three years, highlighting the potential rewards of holding through market volatility. We examine the underlying business trends and investor sentiment behind the numbers.

Jan 30, 2026

World

Private Equity and Sovereign Wealth Funds Profit from UK's Special Educational Needs Crisis

As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.

Jan 30, 2026

Business

Landlords' Tax Return Deadline Looms: A Guide to Navigating Reliefs and Avoiding Penalties

With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.

Jan 30, 2026